ABSTRACT
IMPORTANCE Pericarditis is the most common cardiac manifestation of Systemic Lupus Erythematosus (SLE) and known to recur among patients. Yet, the prevalence and risk factors of recurrent pericarditis in SLE patients are unknown.
OBJECTIVE Determine the frequency and risk factors for the recurrence of pericarditis in patients with SLE.
DESIGN Retrospective analysis of a well-characterized, prospective cohort of SLE patients enrolled between 1988 and 2023.
SETTING A single-center cohort study of a diverse group of SLE patients treated at a tertiary medical center.
PARTICIPANTS Patients diagnosed with pericarditis (n=590) among those enrolled in the Hopkins Lupus Cohort (n=2931).
MAIN OUTCOME Re-occurrence of pericarditis. The SELENA revision of the SLE Disease Activity Index (SLEDAI) was used to define pericarditis. Clinical information was examined for all follow-up encounters after the first episode of pericarditis. Pericarditis that occurred at least six weeks after the first recorded episode was defined as “Recurrent”.
RESULTS Of 2931 patients within the cohort, 590 had a history of pericarditis. In 3.4% of patients, the diagnosis of pericarditis was confirmed via electrocardiogram (EKG) or dedicated imaging, with 100% concordance between clinical and data-based diagnoses. During a median follow-up of 7 years (IQR: 3 – 14), 20% (n=120) of patients experienced recurrent pericarditis (recurrence rate ≈ 0.05 per person-year of follow-up). Most patients (51%) experienced only one recurrence, whereas 49% had ≥2 recurrences. In multivariate analysis, predictors of recurrence included younger age (≥60 years vs. <40, RR 0.11 (0.04, 0.32), P <.001), treatment with prednisone (≥20 mg vs. 0, RR 1.99 (1.17, 3.40), P = 0.012), active SLE disease (SLEDAI ≥3 vs. 0, RR 1.55 (1.21, 2.00), P <.001), and time since initial episode (3-10 years vs. <1, RR 0.32 (0.20, 0.52), P <.001).
CONCLUSION AND RELEVANCE Recurrence is more likely to occur within one year of the onset of pericarditis, and younger patients and those with uncontrolled disease are at greater risk of recurrence. As in the general population, oral prednisone therapy is associated with a higher chance of recurrence in SLE patients, with a dose-dependent effect. These findings set the basis for future studies to define optimal treatment for recurrent pericarditis in SLE patients and suggest that oral corticosteroids should be avoided when treating pericarditis.
Competing Interest Statement
The authors have no financial disclosures immediately relevant to this manuscript to disclose. Dr. Adamo discloses the following other relationships: consultant for Kiniksa Pharmaceutical and co-founder of i-Cordis, LLC, a start-up company focused on developing immunomodulatory small molecules to treat heart failure. All the other authors have no financial interests to report.
Funding Statement
This study was supported in part by NHLBI grants 5K08HLO145108-03 and 1R01HL160716-01, awarded to Luigi Adamo, and NHLBI grant T32-HL007227, awarded to Dr. Jana Lovell. The Hopkins Lupus Cohort is supported by R01DK134625, awarded to Dr. Andrea Fava.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Johns Hopkins University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵□ These authors co-directed this work
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
